Immunology Collaboration and Licensing Deals 2018-2026

Understand the immunology partnering landscape using intelligence from 919 real-world collaboration and licensing deals.

Immunology Collaboration and Licensing Deals 2018-2026 provides comprehensive intelligence on 919 partnering deals involving immunology assets, technologies and development programs.

Immunology is a broad and highly active area of life sciences partnering, encompassing multiple disease areas, mechanisms of action, therapeutic technologies and stages of development. Deal structures reflect both the scientific diversity of the field and the different strategies companies use to access, develop and commercialize innovation.

The report brings this activity together in one resource, enabling users to understand who is partnering, which immunology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in immunology partnering.

Understand the immunology partnering landscape

The report analyzes immunology dealmaking from 2018 to 2026, including:

• Trends in immunology partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active immunology dealmakers
• Leading deals by disclosed value
• How immunology partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark immunology deal financials
• Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading immunology dealmakers and prospective partners
• The report identifies the most active companies in immunology partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking immunology opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant disease areas
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in particular mechanisms, technologies or therapeutic approaches
• Competitors pursuing related external innovation strategies
• For companies seeking to partner an immunology asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across immunology indications and targets
• Immunology encompasses a wide range of therapeutic indications and biological targets with differing scientific, clinical and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad immunology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
• Understand how immunology agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for an immunology partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected immunology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating an immunology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive immunology deal directory
• The report includes a comprehensive directory of 919 immunology collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable immunology transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking immunology opportunities across relevant indications, technologies, targets and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable immunology assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building immunology portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide immunology intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying immunology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.